MedTrace Logo

Thoracal Radiotherapy and Tarceva

NCT02714530 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2021-03-30

No results posted yet for this study

Summary

The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.

Conditions

Interventions

DRUG

Erlotinib

Tarceva daily during radiotherapy course

RADIATION

Radiation

Radiotherapy

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Åslaug Helland, MD PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-01
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02714530 on ClinicalTrials.gov